公开(公告)号：EP1841316A4

公开(公告)日：2008-07-09

申请号：EP06717966

申请日：2006-01-10

Applicant: ROSALIND FRANKLIN UNIVERSITY O

Inventor： RISER BRUCE L ,  PERBAL BERNARD

IPC: A01N37/18 ,  A61K38/00 ,  A61P13/00 ,  A61P35/00

CPC classification number: C07K14/4702 ,  A61K48/00

Abstract: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

公开(公告)号：AU2006203851A1

公开(公告)日：2006-07-13

申请号：AU2006203851

申请日：2006-01-10

Applicant: ROSALIND FRANKLIN UNIVERSITY O

Inventor： PERBAL BERNARD ,  RISER BRUCE L

IPC: A01N37/18

公开(公告)号：CA2597794A1

公开(公告)日：2006-07-13

申请号：CA2597794

申请日：2006-01-10

Applicant: ROSALIND FRANKLIN UNIVERSITY O

Inventor： RISER BRUCE L ,  PERBAL BERNARD

IPC: A01N37/18

公开(公告)号：WO2006074452A2

公开(公告)日：2006-07-13

申请号：PCT/US2006000833

申请日：2006-01-10

Applicant: ROSALIND FRANKLIN UNIVERSITY O ,  RISER BRUCE L

Inventor： RISER BRUCE L ,  PERBAL BERNARD

IPC: A61K48/00

CPC classification number: C07K14/4702 ,  A61K48/00

Abstract: The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and purified CCN3 protein or its fragments or isoforms (or combinations) of CCN3 can be potentially used in the treatment or prevention of these diseases by regulating the expression and/or activity of the CCN2 protein. The level of CCN3 in tissue or body fluids can also be used to predict, diagnose and/or follow the progression of diseases as well as to determine the effectiveness of therapeutic intervention.

Abstract translation: 本发明公开了CCN3​​在与CCN2过表达相关的疾病中的作用，所述疾病包括但不限于肾病，纤维化和癌症。 全长CCN3蛋白或其片段或CCN3的同种型（或组合）参与这些疾病。 通过调节CCN2蛋白的表达和/或活性，分离和纯化的CCN3蛋白或其片段或CCN3的同种型（或组合）可以用于治疗或预防这些疾病。 组织或体液中的CCN3水平也可用于预测，诊断和/或跟踪疾病的进展以及确定治疗干预的有效性。